Compare · BIO vs RPID
BIO vs RPID
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Rapid Micro Biosystems Inc. (RPID): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and RPID operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $10.44B, about 125.3x RPID ($83.3M).
- Over the past year, BIO is up 31.9% and RPID is down 38.2% - BIO leads by 70.1 points.
- RPID has been more active in the news (4 items in the past 4 weeks vs 2 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 10 for RPID).
- Company
- Bio-Rad Laboratories Inc.
- Rapid Micro Biosystems Inc.
- Price
- $390.39+2.45%
- $1.64+1.23%
- Market cap
- $10.44B
- $83.3M
- 1M return
- +23.48%
- -18.41%
- 1Y return
- +31.87%
- -38.23%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2021
- News (4w)
- 2
- 4
- Recent ratings
- 12
- 10
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Latest RPID
- SEC Form 10-Q filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
- Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Kollender Richard S exercised 3,508 shares at a strike of $0.75, increasing direct ownership by 3% to 133,826 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. exercised 1,402 shares at a strike of $0.75, increasing direct ownership by 0.12% to 1,191,973 units (SEC Form 4)
- Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
- Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)